The presentation of tumor antigens and initiation of specific immune responses are the primary responsibilities of professional antigen presenting cells. Dendritic cells (DC) are the most potent antigen presenting cells, and play a crucial role in the induction of primary immune responses. DC are considered one of the best vehicles for delivery of tumor-specific antigens in immunotherapy of cancer. Recently, the applicant and others have demonstrated defective DC function in tumor-bearing animals and in cancer patients. These defects were caused, at least in part, by tumor-derived factors that dramatically inhibited the maturation of CD34+ hematopoietic stem cells into functional DC. The applicant's preliminary data demonstrated defective DC maturation in tumor-bearing mice that might in part be responsible for defective DC function. His preliminary data also demonstrated the appearance of an as yet uncharacterized immature myeloid cell in the dendritic cell fraction from peripheral blood of patients with different types of cancer. All these data suggest that there is a serious defect in DC maturation in cancer. This defect may lead to the production of immature and functionally defective cells. He hypothesizes that these cells also may be involved in active immunosuppression. The presence of these cells may seriously compromise any efforts in immunotherapy of cancer by affecting the function of the host immune system and contaminating the population of DC used in immunotherapy. The purpose of this application is to study tumor-associated defects in DC development in vivo. The ultimate goal of this project is to understand the role of these signals in DC differentiation and to develop immunotherapeutic strategies that counter this effect and enhance the effectiveness of immunotherapeutics in cancer patients. Specifically, the applicant proposes to 1) Characterize the nature of the immature myeloid and immature dendritic cells appearing in peripheral blood of patients with breast, lung and head and neck cancer, and establish the clinical relevance of these cells; 2) Investigate the ability of the immature dendritic cells to suppress immune response and the function of dendritic cells in lymph nodes in patients with cancer; and 3) Study the therapeutic approaches to correct defective DC function in cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084488-02
Application #
6175276
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Finerty, John F
Project Start
1999-04-21
Project End
2000-08-31
Budget Start
2000-04-01
Budget End
2000-08-31
Support Year
2
Fiscal Year
2000
Total Cost
$27,866
Indirect Cost
Name
Loyola University Chicago
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153
Zhou, Jie; Nefedova, Yulia; Lei, Aihua et al. (2018) Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. Semin Immunol 35:19-28
Tang, Chih-Hang; Chang, Shiun; Hashimoto, Ayumi et al. (2018) Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice. Cancer Immunol Res 6:696-710
Tcyganov, Evgenii; Mastio, Jerome; Chen, Eric et al. (2018) Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol 51:76-82
Veglia, Filippo; Perego, Michela; Gabrilovich, Dmitry (2018) Myeloid-derived suppressor cells coming of age. Nat Immunol 19:108-119
Hashimoto, Ayumi; Gao, Chan; Mastio, Jerome et al. (2018) Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice. Cancer Res 78:5644-5655
Dominguez, George A; Condamine, Thomas; Mony, Sridevi et al. (2017) Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. Clin Cancer Res 23:2942-2950
Gabrilovich, Dmitry I (2017) Myeloid-Derived Suppressor Cells. Cancer Immunol Res 5:3-8
Kumar, Vinit; Donthireddy, Laxminarasimha; Marvel, Douglas et al. (2017) Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell 32:654-668.e5
Condamine, Thomas; Dominguez, George A; Youn, Je-In et al. (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 1:
Bronte, Vincenzo; Brandau, Sven; Chen, Shu-Hsia et al. (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150

Showing the most recent 10 out of 55 publications